# A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

> **NCT07017725** · PHASE1,PHASE2 · RECRUITING · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Chronic Immune Thrombocytopenia

## Interventions

- **DRUG:** CID-103

## Key facts

- **NCT ID:** NCT07017725
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-03
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-12-30
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07017725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07017725, "A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07017725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*